Home › Research › Treatments
Functionalised Carbon Nanotubes Enhance Brain Delivery of Amyloid-Targeting Pittsburgh Compound B (PiB)-Derived Ligands
Costa PM, Wang JT, Morfin JF, Khanum T, To W, Sosabowski J, Tóth E, Al-Jamal KT.. Nanotheranostics, 2018-02-15
Topic: Brain proteins, microglia and lab models
Alzheimer's disease (AD) is a neurodegenerative disorder characterised by brain accumulation of toxic protein aggregates, including extracellular amyloid beta (Aβ) plaques, inflammation, neuronal death and progressive cognitive dysfunction. Current diagnostic modalities, based on cognitive tests, fail to detect early AD onset, thus emphasising the need to develop improved methods for pre-symptomatic disease detection. Building on the properties of the Pittsburgh Compound B (PiB), an Aβ-binding molecule suitable to use as positron emission tomography (PET) imaging agent, and aiming at using a more clinically available modality (like magnetic ressonance imaging, MRI), PiB derivatives have been conjugated to the macrocyclic chelator 1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane (DO3A) monoamide. However, these derivatives do not readily cross the highly selective blood-brain barrier (BBB). Taking advantage of the capacity of functionalised carbon nanotubes ( f -CNTs) to cross biological barriers, including the BBB, this manuscript reports on the conjugation of two PiB derivative Gd 3+ complexes - Gd(L 2 ) and Gd(L 3 ) - to multi-walled f -CNTs ( f -MWNTs) and assessment of their in vivo biodistribution and brain uptake. It is shown that Gd(L 2 ) and Gd(L 3 ) can be efficiently loaded onto different f -MWNTs, with significant improvement in brain accumulation of the conjugates compared to the free metal complexes. Overall, this study demonstrates that f -MWNTs have potential to be used as carriers in theranostic applications involving brain delivery of BBB impermeable compounds.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Costa, P. M., Wang, J. T., Morfin, J. F., Khanum, T., To, W., Sosabowski, J., et al. (2018). Functionalised Carbon Nanotubes Enhance Brain Delivery of Amyloid-Targeting Pittsburgh Compound B (PiB)-Derived Ligands. Nanotheranostics. https://doi.org/10.7150/ntno.23125
Vancouver
Costa PM, Wang JT, Morfin JF, Khanum T, To W, Sosabowski J, et al. Functionalised Carbon Nanotubes Enhance Brain Delivery of Amyloid-Targeting Pittsburgh Compound B (PiB)-Derived Ligands. Nanotheranostics. 2018. doi:10.7150/ntno.23125. PMID: 29577020.
BibTeX
@article{costa2018-29577020,
author = {Costa, P. M. and Wang, J. T. and Morfin, J. F. and Khanum, T. and To, W. and Sosabowski, J. and Tóth, E. and Al-Jamal, K. T.},
title = {{Functionalised Carbon Nanotubes Enhance Brain Delivery of Amyloid-Targeting Pittsburgh Compound B (PiB)-Derived Ligands}},
journal = {Nanotheranostics},
year = {2018},
doi = {10.7150/ntno.23125},
pmid = {29577020},
url = {https://doi.org/10.7150/ntno.23125}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- It is shown that Gd(L 2 ) and Gd(L 3 ) can be efficiently loaded onto different f -MWNTs, with significant improvement in brain accumulation of the conjugates compared to the free metal complexes.
- Overall, this study demonstrates that f -MWNTs have potential to be used as carriers in theranostic applications involving brain delivery of BBB impermeable compounds.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 24 of the 58 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Nanotheranostics) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29577020) |
| Free to read | 2 / 2 | Free to read |
| Points | 24 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 24 of the 58 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments
Also tagged “amyloid-targeting”
2 studies in the library carry the topic tag “amyloid-targeting”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.